Temodal gains additional use

The licensed indications for the antineoplastic agent Temodal (temozolomide) have been extended to include the treatment of patients with newly diagnosed glioblastoma multiforme.

Temodal is administered orally together with focal radiotherapy, followed by up to six cycles as monotherapy.

A clinical trial involving 573 patients with newly diagnosed glioblastoma multiforme randomised to receive temozolomide plus radiotherapy or radiotherapy alone showed a significant improvement in survival in the radiotherapy plus temozolomide group compared with the radiotherapy-only group.

Further information: Schering-Plough Ltd, Schering-Plough House, Shire Park, Welwyn Garden City, Herts AL7 1TW. Tel: (01707) 363636.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more